RecruitingPhase 2NCT05398809
Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
Studying Autoimmune polyendocrinopathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Principal Investigator
- Michail S Lionakis, M.D.National Institute of Allergy and Infectious Diseases (NIAID)
- Intervention
- Ruxolitinib(drug)
- Enrollment
- 70 enrolled
- Eligibility
- 12-75 years · All sexes
- Timeline
- 2023 – 2027
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05398809 on ClinicalTrials.govOther trials for Autoimmune polyendocrinopathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07202598Randomized Stepped Wedge Study of Emapalumab in APECED EnteritisNational Institute of Allergy and Infectious Diseases (NIAID)
- RECRUITINGNCT07516886Prognostic Value of Early Postoperative Prostate-Specific Antigen for Oncological Outcomes After Radical ProstatectomyLithuanian University of Health Sciences
- RECRUITINGNCT05578105Prevalence and Genetic Alternation of Autoimmune Polyglandular Syndrome Type II in TaiwanNational Taiwan University Hospital